FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Para fines de investigación únicamente. Aviso completo →

Volver a Biblioteca de Investigación
PubMedReview

Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72 to membrane.

Jia Hong, Zhou Lyu-Chen, Chen Yong-Feng, Zhang Wei, Qi Wei, Wang Peng, Huang Xiao, Guo Jian-Wei, Hou Wai-Fang, Zhang Ran-Ran
Theranostics2024DOI: 10.7150/thno.100321
MOTS-cTRIM72

Puntuación de Calidad

6/10

Citas

0

Sujetos

No Humanos

Análisis de Peptide Contacts

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of MOTS-c, TRIM72 in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. Specifically: the sample size is modest, which limits statistical power and the ability to detect smaller but clinically meaningful effects. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: A solid contribution to MOTS-c, TRIM72 research. Worth reading alongside other studies on the same compounds for a balanced picture.

Encuentros Clave

The review discusses the role of mitochondria-encoded peptide MOTS-c in plasma membrane repair by facilitating the translocation of TRIM72 to the cell membrane, suggesting a novel mechanism for cellular protection and repair.

Limitaciones

As this is a review paper, it does not present new experimental data but rather synthesizes existing literature. The conclusions are based on previous studies which may have their own limitations in terms of sample size, study design, or animal models used.

Cómo Interpretar esta Investigación

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Análisis de Peptide Contacts

Highlighting the novel mechanism by which MOTS-c and TRIM72 contribute to plasma membrane repair, emphasizing potential implications for future therapeutic interventions.

MOTS-cTRIM72

MOTS-c: A New Player in Cellular Protection Through Membrane Repair

Published: May 16, 2026 | Source: Theranostics (2024) | Category: MOTS-c, TRIM72

Overview

A recent review published in Theranostics highlights the role of mitochondria-encoded peptide MOTS-c in facilitating plasma membrane repair by promoting the translocation of TRIM72 to cell membranes. This discovery could pave the way for innovative therapeutic strategies targeting cellular damage and repair mechanisms.

Study Background

Previous research has shown that mitochondrial peptides play crucial roles in various physiological processes, including metabolism and stress response. However, their involvement in direct cellular protection through plasma membrane repair was less understood until now. The review synthesizes existing literature to elucidate the mechanism by which MOTS-c interacts with TRIM72, a protein known for its role in cell survival pathways.

What the Research Found

The review emphasizes that MOTS-c acts as a signaling molecule within cells, facilitating the movement of TRIM72 from intracellular locations to the plasma membrane. This translocation is critical during cellular stress or injury when rapid repair mechanisms are necessary to maintain cell integrity and function. The study suggests that without MOTS-c, the efficiency of TRIM72 in reaching the damaged sites on the plasma membrane would be significantly reduced.

What This Means for Peptide Users

While this research does not directly offer new peptides for therapeutic use, it opens avenues for developing drugs or treatments that mimic or enhance the function of MOTS-c. Future studies might explore how to increase the production or activity of MOTS-c in cells affected by diseases characterized by membrane damage and repair deficits.

Limitations and Caveats

As a review paper, this study does not present new experimental data but rather synthesizes findings from previous research. Therefore, its conclusions are contingent on the limitations inherent in earlier studies such as sample size, animal model applicability to human conditions, and variability across different cell types or disease states.

How This Compares to Previous Research

The review aligns with growing interest in mitochondrial peptides' roles beyond energy metabolism. It builds upon earlier work that hinted at MOTS-c’s broader cellular functions but did not specifically focus on its role in plasma membrane repair mechanisms. The novel aspect here is the detailed exploration of how MOTS-c interacts with TRIM72 to facilitate membrane repair.

Our Analysis

PeptideVault views this review as a significant contribution to understanding mitochondrial peptides' multifaceted roles in cellular physiology and pathology. However, it underscores the need for further experimental validation to confirm the mechanisms described and explore their therapeutic potential fully.

Key Takeaways

  • MOTS-c Facilitates Repair: MOTS-c plays a crucial role in plasma membrane repair by assisting TRIM72's translocation.
  • Potential Therapeutic Targets: The findings suggest possible new targets for therapies aimed at enhancing cellular protection mechanisms.
  • Further Research Needed: While promising, the conclusions require confirmation through additional experimental studies.

Original Source

Citation: Jia Hong, Zhou Lyu-Chen, Chen Yong-Feng et al. (2024). Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72 to membrane.. Theranostics. DOI: 10.7150/thno.100321

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Nota del Editor

Este análisis fue escrito por el equipo de investigación de Peptide Contacts para hacer hallazgos complejos accesibles a la comunidad de péptidos. Se anima a los lectores a revisar el paper fuente para metodología y datos completos. Para más sobre MOTS-c, explore nuestros guias de investigación.

Cita

Jia Hong, Zhou Lyu-Chen, Chen Yong-Feng et al.. (2024). Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72 to membrane.. Theranostics. https://doi.org/10.7150/thno.100321

Ver texto completo en PubMed

Papers Relacionados

Explorar más

Este contenido se deriva de investigación revisada por pares para fines educativos solo. No constituye consejo médico. Consulte siempre a un proveedor de atención médica calificado antes de usar cualquier terapia basada en péptidos.